In light of the data recently published in melanoma regarding the potential synergistic effect of anti-CTLA4 and anti-RANKL drugs described in preclinical model [24], our observation could open the possibility for a clinical trial invastigatig the combination of immunotherapeutic agents plus anti-RANKL drug also in metastatic nasopharyngeal cancer. Here, CTLA4 is linked to melanoma.